DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 3 Jeff Emmick - 3 Dr - 2 Eli Lilly's - 2 Eli Lilly’s - 1 Zepbound - 1 Mike Blake - 1 tirzepatide - 1
Top related locs:
New York City U.S San Diego , California Chicago , Illinois San Diego GLP
Top related orgs:
U.S . Food - 1 Drug Administration - 1 FDA - 1 OSA - 1 Wegovy - 1 DIEGO - 1 Novo Nordisk's - 1 American Diabetes Association - 1

Search resuls for: "Jeff Emmick"


4 mentions found


☆ Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
  + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. Zepbound was more effective than a placebo at reducing the severity of obstructive sleep apnea, or OSA, in patients with obesity after a year, according to preliminary data from both trials. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity. Zepbound has slipped into shortages since receiving approval in the U.S. for weight management in November.
Persons: Eli Lilly’s, Eli Lilly, Zepbound, Dr, Jeff Emmick, Eli Lilly's Organizations: U.S . Food, Drug Administration, FDA, OSA Locations: New York City, U.S
☆ Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
  + stars: | 2023-07-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Mike Blake | ReutersTrial resultsOne trial, called Surmount-4, evaluated more than 600 people over two periods. Patients took tirzepatide for 36 weeks and achieved 21.1% weight loss on average. Overall, patients who stayed on the drug lost 26% of their weight on average after 88 weeks. The experimental obesity drug helped patients lose around 24% of their weight, setting a new bar for weight loss in mid-stage clinical trials. A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023.
Persons: Eli Lilly, Mike Blake, tirzepatide, Dr, Jeff Emmick, Eli Lilly's, Eli Lilly's tirzepatide, Jim Vondruska Organizations: Wegovy Locations: San Diego , California, Chicago , Illinois
☆ Analysis: Weight loss drug candidates multiply, spurring hopes of better outcomes, lower costs
  + stars: | 2023-06-27 | by ( Deena Beasley | ) www.reuters.com   time to read: +5 min
More than 40% of Americans are obese, according to the U.S. Centers for Disease Control and Prevention, and demand is strong for treatments to reduce body weight as well as maintain weight loss. The company said it would continue to develop its twice-daily weight loss drug candidate. Structure Therapeutics (GPCR.O) is developing oral obesity drugs that it says are simpler to manufacture than the current injectables. "We define weight loss quality as the percentage of weight loss attributed to fat loss," said Versanis Chief Scientific Officer Lloyd Klickstein. "With diets, bariatric surgery, incretin drugs or other weight loss drugs, two-thirds to three-quarters of the weight loss is fat, but one-quarter to one-third is lean."
Persons: Robert Gabbay, Eli Lilly, Lilly's, Wegovy, Mico Guevarra, Lilly, Jeff Emmick, Ray Stevens, Boehringer Ingelheim, Versanis, Lloyd Klickstein, Chaguturu, Deena Beasley, Michele Gershberg, Jamie Freed Organizations: DIEGO, Novo Nordisk's, American Diabetes Association, Novo, U.S . Centers for Disease Control, ADA, Pfizer, Therapeutics, Zealand Pharma, Novartis, CVS Health, Aetna, Thomson Locations: San Diego, GLP
☆ Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds
  + stars: | 2023-04-27 | by ( Spencer Kimball Annika Kim Constantino | Spencer Kimball | Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Patients who took Eli Lilly 's weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their body weight, the company said in clinical trial results released Thursday. Eli Lilly plans to complete its application for Food and Drug Administration approval of the drug in the coming weeks and expects regulatory action as early as later this year. The FDA approved tirzepatide for Type 2 diabetes last year, but the drug is not cleared for weight loss. The approval would open "up the opportunity for many more people to benefit from tirzepatide," Eli Lilly CEO David Ricks said Thursday on CNBC's "Squawk Box." He added that the drug sets a "new bar for weight loss and people with diabetes."
0 next >>
Total: 4